Trials / Completed
CompletedNCT05165394
Study to Evaluate the Efficacy and Safety of Once-Weekly Oral NBI-1065846 in the Treatment of Anhedonia in MDD
A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study to Evaluate the Efficacy and Safety of Once-Weekly Oral NBI-1065846 in the Treatment of Anhedonia in Major Depressive Disorder (TERPSIS STUDY)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 93 (actual)
- Sponsor
- Neurocrine Biosciences · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the efficacy of NBI-1065846 compared with placebo on improving symptoms of anhedonia in participants with major depressive disorder (MDD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo | Tablets for oral administration |
| DRUG | NBI-1065846 | Tablets for oral administration |
Timeline
- Start date
- 2021-11-30
- Primary completion
- 2023-07-07
- Completion
- 2023-09-13
- First posted
- 2021-12-21
- Last updated
- 2024-07-31
- Results posted
- 2024-07-31
Locations
23 sites across 2 countries: United States, Puerto Rico
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05165394. Inclusion in this directory is not an endorsement.